Hyman Charles D Grows Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Hyman Charles D grew its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 20.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 30,128 shares of the medical equipment provider’s stock after acquiring an additional 5,055 shares during the quarter. Hyman Charles D’s holdings in Intuitive Surgical were worth $10,164,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ISRG. WCM Investment Management LLC purchased a new stake in shares of Intuitive Surgical during the fourth quarter worth approximately $575,536,000. International Assets Investment Management LLC raised its position in Intuitive Surgical by 32,360.5% during the 4th quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock worth $231,721,000 after buying an additional 684,749 shares during the last quarter. Alphinity Investment Management Pty Ltd lifted its stake in shares of Intuitive Surgical by 113.2% in the 4th quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock worth $430,525,000 after acquiring an additional 677,455 shares during the period. J.P. Morgan Private Wealth Advisors LLC purchased a new stake in shares of Intuitive Surgical in the third quarter valued at about $178,667,000. Finally, Quadrature Capital Ltd raised its holdings in Intuitive Surgical by 466.2% during the third quarter. Quadrature Capital Ltd now owns 340,644 shares of the medical equipment provider’s stock worth $99,601,000 after purchasing an additional 280,480 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Insider Activity

In other Intuitive Surgical news, SVP Mark Brosius sold 196 shares of the firm’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total transaction of $78,400.00. Following the completion of the transaction, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at approximately $736,800. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, EVP Myriam Curet sold 481 shares of the company’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $386.09, for a total transaction of $185,709.29. Following the completion of the transaction, the executive vice president now directly owns 298 shares in the company, valued at approximately $115,054.82. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Mark Brosius sold 196 shares of the business’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total transaction of $78,400.00. Following the transaction, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at approximately $736,800. The disclosure for this sale can be found here. In the last three months, insiders sold 147,927 shares of company stock worth $57,064,459. 0.80% of the stock is currently owned by insiders.

Intuitive Surgical Stock Down 2.1 %

Shares of ISRG traded down $8.28 during mid-day trading on Wednesday, reaching $380.37. 1,107,969 shares of the stock traded hands, compared to its average volume of 1,601,620. The firm has a market cap of $134.92 billion, a price-to-earnings ratio of 68.66, a P/E/G ratio of 4.93 and a beta of 1.39. The stock has a fifty day simple moving average of $385.34 and a 200 day simple moving average of $351.97. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The company had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. During the same period in the prior year, the company posted $1.00 EPS. The firm’s revenue for the quarter was up 11.5% on a year-over-year basis. On average, equities research analysts expect that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have issued reports on ISRG. BTIG Research boosted their target price on Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a research report on Friday, April 19th. StockNews.com downgraded shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. Piper Sandler upped their target price on shares of Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a research report on Friday, April 19th. Mizuho lifted their price target on shares of Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a research report on Thursday, January 25th. Finally, Jefferies Financial Group raised their price target on Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a research report on Friday, April 19th. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $396.17.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.